Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 527 million and 583 million CNY, representing a year-on-year growth of 90% to 110% compared to 277.51 million CNY in the same period last year[1]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 501.2 million and 557.2 million CNY, reflecting a year-on-year increase of 91% to 112% compared to 262.96 million CNY last year[1]. Non-Recurring Gains and Losses - The impact of non-recurring gains and losses on net profit for the first half of 2024 is approximately 25.8 million CNY, mainly from government subsidies and returns from financial products[6]. Operational Efficiency - The company has experienced a favorable external policy environment, leading to a significant increase in operating income year-on-year[2]. - The company has successfully reduced unit production costs due to increased production scale and a decrease in the expense ratio compared to the previous year[2]. Caution for Investors - The preliminary financial data provided in the earnings forecast has not been audited by registered accountants, and investors are advised to make cautious decisions[7].
健帆生物(300529) - 2024 Q2 - 季度业绩预告